

Accepted Manuscript

Title: Reproductive Outcomes after Fertility-Sparing Surgery for Focal and Diffuse Adenomyosis: a Systematic Review

Author: Justin Tan, Sophie Moriarty, Omur Taskin, Catherine Allaire, Christina Williams, Paul Yong, Mohamed A. Bedaiwy

PII: S1553-4650(17)31361-4
DOI: <https://doi.org/10.1016/j.jmig.2017.12.020>
Reference: JMIG 3380

To appear in: *The Journal of Minimally Invasive Gynecology*

Received date: 19-10-2017
Revised date: 2-12-2017
Accepted date: 23-12-2017

Please cite this article as: Justin Tan, Sophie Moriarty, Omur Taskin, Catherine Allaire, Christina Williams, Paul Yong, Mohamed A. Bedaiwy, Reproductive Outcomes after Fertility-Sparing Surgery for Focal and Diffuse Adenomyosis: a Systematic Review, *The Journal of Minimally Invasive Gynecology* (2018), <https://doi.org/10.1016/j.jmig.2017.12.020>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



1 **Reproductive Outcomes after Fertility-Sparing Surgery for Focal and Diffuse Adenomyosis:**
2 **A Systematic Review**

3 Justin Tan¹, Sophie Moriarty¹, Omur Taskin¹, Catherine Allaire¹, Christina Williams¹, Paul Yong¹
4 and Mohamed A. Bedaiwy MD, PhD¹

5
6 ¹Department of Obstetrics & Gynecology, The University of British Columbia, Vancouver, Canada.

7
8 Corresponding author and person to whom reprint requests should be addressed:

9 Mohamed A. Bedaiwy, MD, PhD

10 Division of Reproductive Endocrinology & Infertility

11 Department of Obstetrics & Gynecology,

12 The University of British Columbia,

13 D415A-4500 Oak Street, Vancouver, BC, V6H 3N1, Canada

14 Phone: +1-604-875-2000 ext 4310, Fax: +1-604-875-2725

15 Email: mohamed.bedaiwy@cw.bc.ca

16
17 **Conflict of Interests:** None declared.

18
19 **Funding sources:** None.

20 **Prior publications:** None.

21 **Clinical trial registry number:** N/A.

22 **IRB:** N/A

23
24 **Word count:** 3961 words

25

26

27

28

29 **ABSTRACT**

30 Among the variety of treatment options to improve reproductive outcomes for infertile women with
31 adenomyosis (AD), uterine conserving surgery has demonstrated varying success. Hence, we
32 conducted a systematic review around the topic of fertility-sparing surgery across 18 studies and
33 1396 infertile women with focal and diffuse AD. Patients with focal AD demonstrated mean
34 pregnancy and miscarriage rates of 52.7% (range:14.3-77.5%) and 21.1% (range:0-44.4%),
35 respectively, while patients with diffuse AD had a mean pregnancy and miscarriage rate of 34.1%
36 (range:9.4-100%) and 21.7% (range:12.5-33.3%), respectively. Uterine rupture and preterm birth
37 was observed in 6.8% (3/44) and 4.5% (2/44) of pregnant patients with diffuse AD vs. 0% (0/35)
38 and 10.9% (12/110) of patients with focal AD, respectively. No significant differences were
39 observed between natural conception vs. ART with or without GnRHa pre-treatment. Overall,
40 patients with focal AD appeared to have higher pregnancy rates after conservative surgery
41 compared to diffuse AD, while a higher incidence of uterine rupture was reported after surgery for
42 diffuse AD. However, significant heterogeneity precludes any direct comparison and prospective
43 controlled trials are required to further elucidate the benefits of fertility preserving surgery over
44 medical or expectant management for AD-related infertility. In view of the debatable benefits of
45 conservative surgery and the possible increase in adverse pregnancy outcomes particularly in
46 cases of diffuse adenomyosis, clinicians should consider surgery on a case-by-case basis as it
47 may be appropriate for women with concurrent AD-associated pelvic pain or menorrhagia, younger
48 infertile women who have failed medical management or older women with infertility despite ART,
49 and those with a history of recurrent pregnancy loss or implantation failure.

50

51

52 **Keywords:** Adenomyosis; fertility-sparing surgery; systematic review

53

54

55 **INTRODUCTION**

56 Adenomyosis is a complex disease process that manifests in a multitude of ways. Among
57 reproductive age women, numerous theories have discussed the possible causes of infertility
58 including an impaired uterine system of sperm transport, uterine dysperistalsis (resulting in
59 reduced embryo implantation), abnormal concentrations of free radicals in the uterine environment,
60 and altered endometrial vascularization and decidualization [1-3]. Anatomically, the disease
61 process occurs due to the presence of heterotopic endometrial stroma and glands within the
62 myometrium that leads to junctional zone dysfunction (JZ) and subsequent smooth muscle
63 hyperplasia and hypertrophy [4]. AD often presents concurrently with endometriosis and
64 leiomyomas, with a co-prevalence rate of 6-22% and 35-55%, respectively. Similarly, AD has been
65 found on MRI in 77% of infertile women with endometriosis compared to 22% of those without
66 endometriosis [5]. Unlike endometriosis and uterine fibroids, however, AD exhibits a unique quality
67 in the varying extent of disease, ranging from diffuse myometrial hypertrophy encasing the uterus
68 to more discrete focal lesions known as adenomyomas. Given the myriad of possible presentations
69 and concurrence with other gynecologic treatments, diagnosis and treatment of AD has proven
70 exceptionally difficult.

71 Population estimates suggest that approximately 20% of cases of AD involve women under 40
72 years old, while 80% of cases are diagnosed among women in the fourth or fifth decades of life [6].
73 Depending on individual patient goals for symptom-relief or improved fertility, the range of available
74 treatments range from conservative medical management, fertility-sparing surgery, or definitive
75 hysterectomy [7,8]. Although definitive hysterectomy offers curative results among women with
76 AUB and pelvic pain who have completed childbearing, fertility-sparing options such as hormonal
77 therapy with gonadotropin-releasing hormone agonists (GnRH-a) and conservative surgical
78 procedures have variable rates of success [9-13]. Specifically in regards to uterine-conserving
79 surgical options to improve fertility outcomes, a recent review of available options emphasized the
80 paucity of good quality evidence and importance of further research to optimize treatment options
81 and improve reproductive outcomes among women with AD who wish to preserve their fertility [14].

82 Several recent systematic reviews and meta-analyses have investigated the relationship between
83 adenomyosis, surgery, pelvic pain, and infertility. Vercellini et al [15] examined the effect of
84 adenomyosis on IVF/ICSI outcomes with and without GnRHa pre-treatment and demonstrated that
85 women with AD had a significantly lower clinical pregnancy rate (relative risk [RR]: 0.72; 95%
86 confidence interval [CI]: 0.55-0.95) and twofold increased risk of miscarriage (RR: 2.12; 95% CI:
87 1.20-3.75) after IVF compared to those without AD. However, no assessment of pregnancy
88 outcomes after surgery or through natural conception are discussed. Conversely, Younes et al [16]
89 conducted a systematic review of post-surgical outcomes for adenomyosis that were mainly
90 indicated for treatment of menorrhagia and dysmenorrhea, although in a subgroup analysis of
91 fertility outcomes after surgery, they noted significant heterogeneity between studies and
92 concluded that surgery is effective for symptom relief in 75% of cases and may also improve
93 fertility outcomes. Similarly, Dueholm et al [17] included a sub-analysis of reproductive outcomes
94 after cyto-reductive surgery among 338 women with AD and noted a slightly higher pregnancy rate
95 (PR) and live birth rate (LBR) after IVF/ICSI in patients who underwent surgery. However, once
96 again, the authors noted significant heterogeneity between included studies, adverse pregnancy
97 outcomes were not discussed, and no comparison was made between focal and diffuse
98 adenomyosis.

99 The primary purpose of this systematic review was to evaluate reproductive outcomes after
100 conservative surgery for both focal and diffuse adenomyosis specifically in patients desiring
101 fertility. In doing so, we have taken a different approach to previous reviews which primarily
102 investigated the role of conservative surgery for relieving symptoms (pain, dysmenorrhea)
103 associated with adenomyosis [16] or the effect of adenomyosis on reproductive outcomes after
104 ART [15,17,18]. Ultimately, we hypothesize that good reproductive outcomes may be achieved
105 through both natural conception and IVF after fertility-sparing surgery for adenomyosis. Since focal
106 AD is well circumscribed and more amenable to complete excision, pregnancy outcomes may be
107 improved after surgical cytoreduction compared to patients with diffuse AD. Furthermore, adverse
108 pregnancy events are likely to be higher among patients with diffuse AD due to the presence of
109 more extensive disease that may compromise uterine function and integrity during pregnancy.

110 **METHODS**

111 This systematic review was conducted according to the Preferred Reporting Items for Systematic
112 Reviews and Meta-analysis (PRISMA) guidelines 6 [19].

113 Three databases were reviewed: Ovid MEDLINE 1946 to present, EMBASE 1947 to July 25th 2017
114 and Evidence-Based Medicine Reviews (EMBR). The following subject headings and key words
115 were searched: AD OR adenomyos* OR adenomyom* OR junctional zone AND fertility OR
116 infertility OR pregnan* OR concepti* OR IVF OR assisted reproduct* OR obstetric outcome OR
117 reproductive outcome AND surger* OR operati* OR adenomyomectomy* OR cytoreductive.

118 All original research articles including randomized and non-randomized controlled trials, cohort
119 studies, patient series and case reports were included. All included studies reported reproductive
120 outcomes after NC or ART in infertile couples with focal or diffuse AD. Additional studies were
121 extracted from the references in the full text articles. Articles were restricted to English only and we
122 also considered published abstracts from conferences.

123 The search produced a total of 875 results: 248 from MEDLINE, 592 from EMBASE and 35 from
124 EMBR. An additional study was included from the reference list of a previous review [20].
125 Following duplicate removal, 723 remained and each title and abstract was reviewed by two
126 reviewers. Subsequently, 124 full texts were selected for full review and an additional 106
127 excluded, leaving 16 studies that were included for quantitative analysis and an additional two
128 studies included for qualitative analysis. Reasons for exclusion included: case reports, non-English
129 articles, systematic reviews, and studies that failed to report fertility outcomes, those pertaining to
130 endometriosis instead of AD, and also studies that did not include uterine-conserving surgery as
131 an intervention. Two reviewers (SM and OT) independently searched and reviewed the retrieved
132 articles and results were compared. Any disagreement was resolved by discussion. Two specific
133 studies excluded were Nishida et al [21] due to a short 3-month follow-up which precluded their
134 ability to report fertility outcomes, and Dai et al [22] which did not exclusively enroll patients
135 desiring fertility-conserving surgery. In addition, two studies were excluded from quantitative

136 comparison, Tamura et al [23] and Chang et al [24], because they included duplicate patients from
137 other studies that were already included in this review.

138 The following data was retrieved from all articles: study design, year of publication, diagnostic
139 method, surgical technique, pregnancy rate and miscarriage rate after surgical treatment, and
140 complications if applicable. As outlined in Supplemental Table 1, the Cochrane Collaboration's
141 Risk of Bias Tools for Non-Randomized Studies was used to evaluate the methodologic quality
142 and potential risk of bias of included studies.

143 In agreement with previous reviews, statistical analysis was deemed unsuitable for quantitative
144 interpretation of this data due to the heterogeneity of the studies involved. With respect to
145 quantitative comparisons, pregnancy rate was calculated according to the number of unique
146 women who became pregnant, thereby excluding cases where a woman achieved more than one
147 pregnancy. Conversely, live birth and miscarriage rates were calculated according to the total
148 number of pregnancies rather than the number of unique pregnant women.

149 **RESULTS**

150 This review included 18 studies for qualitative analysis: 10 retrospective [9,11,20-23,25-29] and 8
151 prospective studies [12,13,22,24,30-33] with a combined cohort of 1396 women with AD who
152 underwent uterine preserving surgery (Figure 1). As was previously explained, two studies were
153 treated separately given the overlap in study groups; among the 16 remaining studies (Table 1),
154 mean age of the study population was 34.1-years-old (range 20-51), and mean follow-up post-
155 surgery was 44 months (range 3-120). Eight studies included patients with focal AD, seven
156 studies among women with diffuse AD, and one study included patients with both types of AD.
157 Most of the studies diagnosed AD by TVUS or MRI and in the majority of cases, observed
158 adenomyotic lesions were located in the posterior wall of uterus. 5 studies involved laparoscopic
159 approaches to surgery, while 12 others reported surgical intervention by laparotomy (Table 2).

160 Reproductive outcomes following conservative surgery alone for focal and diffuse AD are
161 summarized in Figure 2. Overall, PR appeared to be better in the focal AD group following surgery

162 compared to the diffuse AD group (52.7% vs 34.1%) and miscarriage rates were comparable
163 (21.1% vs 21.7%). However, due to the significant heterogeneity between studies and lack of
164 appropriate control groups, any direct comparison would be unreliable. Among studies that
165 assessed surgical intervention alone, similar outcomes were observed between the focal and
166 diffuse AD groups (PR: 49.1% vs. 38.5%, MR 27.6% vs. 16.2%, respectively) as shown in Figure
167 2. However, among studies that evaluated the effects of combined surgery and medical treatment,
168 focal AD yielded improved PR, LBR, and MR compared to diffuse AD (67.1%, 61.3%, 11.6% vs.
169 17.6%, 9.8%, 33.3%, respectively). Interestingly, among studies that reported reproductive
170 outcomes after medical treatment alone [9,23,28,29,32], reproductive outcomes appeared to be
171 worse compared to women who underwent surgery. More specifically, women with focal AD
172 demonstrated a PR of 14.3% (5/35) and MR of 40% (2/5) compared to 10% (6/60) and 33.3% (2/6)
173 in the diffuse AD group.

174 As shown in Figure 3, similar PR were observed after NC (range: 9.4% to 46.4%) and ART (range:
175 28.6% to 33.3%) for diffuse AD. Similarly, PR in cases of focal AD ranged from 14.3% to 77.5%
176 after natural conception, while only one study reported focal AD pregnancy outcomes after ART
177 [27]. None of the studies reported information regarding the number of cycles required to achieve
178 pregnancy among patients undergoing ART.

179 Although case reports that discussed adverse obstetrical outcomes after surgery for AD were
180 excluded, 8 studies that met eligibility criteria also reported various perinatal outcomes among
181 patients with focal and diffuse AD. Based on the limited number of patients, uterine rupture was
182 observed in 3/44 (6.8%) of pregnant patients after conservative surgery for diffuse AD while no
183 reported cases of uterine rupture were observed in the focal AD group. Similar rates of ectopic
184 pregnancy, placenta accreta, preterm birth, and retained placenta were observed between groups
185 (Table 3).

186 **DISCUSSION**

187 Management of women with adenomyosis-associated subfertility is highly controversial and there
188 remains an overall lack of consensus regarding the value of conservative surgery with or without
189 medical management to improve reproductive outcomes [6]. Previous systematic reviews and
190 meta-analyses have demonstrated an increased miscarriage rate and poor pregnancy outcomes
191 with AD [15-17]. Oftentimes, these findings have been correlated to the extent and degree of
192 abnormal uterine myometrium in AD that is functionally distinct both in terms of cell density and
193 immunohistochemistry from that of normal uteri [34]; for instance, adverse IVF/ICSI outcomes and
194 increased miscarriage rates in AD have been observed with a myometrial thickness of more than
195 2.5 cm on TVUS [35]. Hence, it would appear plausible that surgical removal of adenomyosis
196 would reduce the deleterious effects of the disease [36]. Indeed, surgery has proven effective for
197 control of symptoms related to adenomyosis and probable AD-related infertility [16,17,37]. Since
198 focal adenomyosis is often well circumscribed and confined to a limited portion of the uterus,
199 complete excision and maximal cytoreduction is typically easier; hence, the beneficial effect of
200 fertility-sparing surgery should be more pronounced than for diffuse AD.

201 Our review of the currently available evidence identifies many areas of heterogeneity between
202 studies that report reproductive outcomes after surgery for AD-related infertility. Beyond the
203 intrinsic variability among patients with AD, the absence of standardized surgical techniques and
204 differences in surgeon skill and experience further contribute to this heterogeneity. Nevertheless,
205 this review highlights several important takeaways (Table 4) regarding the reproductive outcomes
206 after fertility-sparing surgery for focal and diffuse AD.

207 Focal vs. Diffuse Adenomyosis

208 To the best of our knowledge, this is the first systematic review that evaluates differences in
209 reproductive between focal and diffuse adenomyosis after fertility-sparing surgery. Overall, our
210 results demonstrated higher mean pregnancy and live birth rates, yet similar miscarriage rates in
211 cases of focal vs. diffuse AD after conservative surgery. Although significant heterogeneity
212 between studies limits the overall validity of such a comparison (Supplemental Figure 1), these
213 results offer avenues for further study as it is possible that the type and extent of disease (focal vs.

214 diffuse) would influence treatment outcomes. Furthermore, there is preliminary evidence that
215 improved pregnancy outcomes after fertility-conserving surgery may depend on the size of
216 adenomyotic lesions being resected, particularly those causing intrauterine cavity distortion among
217 patients with a concurrent history recurrent implantation failure [11,37,38]. Other specific criteria
218 that may influence the benefits of surgery include patient age, as Kishi et al [11] found a significant
219 difference in fertility outcomes after surgical intervention among women <39 years old compared to
220 >40, with pregnancy rates of 48% and 22.2% and miscarriage rates of 13.9% and 83.3%
221 respectively. Finally, among patients with concurrent dysmenorrhea or menorrhagia along with
222 infertility, conservative surgery may be a cost-effective treatment option for patients since surgery
223 has been shown to aid in symptom reduction [37]. In this way, surgery could be individualized and
224 considered for specific patients where it has the potential to be beneficial.

225 ART, NC, & Pre-treatment with GnRHa

226 Although not addressed in prior systematic reviews, our study also demonstrates that acceptable
227 and comparable pregnancy rates can be achieved through both NC and ART after fertility-
228 conserving surgery for focal and diffuse AD. In a recent meta-analysis, Younes et al [18]
229 demonstrated that focal AD was associated with improved IVF outcomes compared to diffuse AD
230 (OR 1.36), although the results were not statistically significant. Park et al [39] also reported higher
231 clinical pregnancy rates in focal AD compared to diffuse type after surgery in infertile women
232 undergoing ART. However, these prior studies did not assess whether pregnancy outcomes after
233 ART were improved over conservative expectant management. Conversely, the results of our
234 review are consistent with a recent retrospective survey by Tamura et al [23], which showed no
235 statistical difference in post-operative pregnancy rates after ART compared with infertility
236 treatments other than ART in cases of both focal and diffuse AD; interestingly, however, they also
237 demonstrated significantly lower miscarriage rates in the focal adenomyosis group.

238 Overall, significant variability in reproductive outcomes have been reported after ART among
239 patients with adenomyosis [15,17,18]. Based on the included studies in this review (Supplemental
240 Figure 2), this variability in outcomes observed can likely be attributed to significant heterogeneity

241 in patient age, duration/type of infertility, and coexistence of other disorders such as endometriosis
242 and leiomyoma. Nevertheless, most included studies reported a high miscarriage rate after surgery
243 in women with both focal and diffuse AD. Ultimately, any operative intervention that compromises
244 the integrity uterine cavity may contribute to adverse pregnancy outcomes; hence, this is a topic
245 that warrants further research in prospective studies.

246 As shown in Figure 2, a combination of surgery and GnRHa pre-treatment appeared to improve
247 pregnancy and live birth rates compared to surgery alone in cases of focal adenomyosis;
248 conversely, surgery alone yielded the highest pregnancy rates among cases of diffuse
249 adenomyosis. Since the GnRH receptor is found in adenomyotic lesions [40], it is plausible that the
250 anti-proliferative and anti-inflammatory effects of GnRH on the myometrium and apoptosis
251 induction would be more beneficial in cases of extensive diffuse disease compared to focal AD,
252 although the heterogeneity between studies precludes any definitive conclusion. Younes and
253 Tulandi [18] found that GnRHa prior to IVF yielded improved pregnancy outcomes, yet Tamura et
254 al [23] found similar pregnancy and miscarriage rates among infertile women who were pre-treated
255 with GnRHa prior to ART compared to women without any treatment (52.6% and 52.2% vs 41.4%
256 and 34.0%, respectively) [23]. Interestingly, Tamura et al [23] also noted a slightly improved
257 pregnancy and miscarriage rate after medical pre-treatment in cases of focal compared to diffuse
258 AD.

259 Obstetrical Complications & Timing after Surgery

260 Pregnancy-related uterine rupture rates after conservative surgery for AD are sparsely reported in
261 the literature, yet most likely depend on a variety of factors including the extent of disease, amount
262 of AD that is surgically resected, and specific surgical technique [16]. In general, diffuse AD
263 involves a greater proportion of the myometrium and is less well circumscribed than focal AD,
264 hence it is less amenable to maximal cytoreduction and surgical excision may confer an increased
265 risk of compromised uterine integrity. Indeed, uterine rupture was reported in 3 of 44 pregnant
266 cases (6.8%) reported after conservative surgery for diffuse AD, while no cases were reported
267 among cases of focal AD (Table 3). However, varying surgical techniques and extent of disease

268 limit the comparability of adverse outcomes among included studies and further prospective
269 studies are required to more accurately assess the incidence of uterine rupture after surgical
270 removal of AD. Until more reliable evidence is available, surgeons should generally adopt a more
271 conservative approach for women who wish to preserve their fertility since diligent reconstruction
272 and careful avoidance of removing normal myometrial tissue are essential to ensure sufficient wall
273 integrity that can sustain future pregnancy [46]. Although successful pregnancies have been
274 reported as early as 3 months after surgery for AD [20,47], further research is also necessary to
275 determine the optimal waiting time based on individual patient characteristics to ensure adequate
276 healing before attempting to conceive.

277 It is also important to recognize a possible association between adenomyosis and various perinatal
278 complications including miscarriage, preterm delivery, preterm premature rupture of membranes,
279 small-for-gestational age, and fetal malpresentation [41-44]. Indeed, Tamura et al [43] conducted a
280 multicenter retrospective survey and concluded that pregnancy complications were related to the
281 size of adenomyotic lesion and more diffuse AD was associated with higher rates of pregnancy-
282 induced hypertension and uterine infection compared to women with focal AD. However, they
283 found no overall difference in pregnancy complications among women with AD who received no
284 pre-treatment compared to those who were treated medically or surgically. Notwithstanding, it is
285 possible that the mere presence of adenomyosis may impair uterine function and lead to a pro-
286 inflammatory state that adversely affects pregnancy outcomes [43,45]. In this way, surgical
287 removal of adenomyotic tissue may alleviate certain complications, but this must be
288 counterbalanced by the inherent disadvantages of creating a possibly defective uterine wall.

289 Limitations & Future Considerations

290 While many previous studies address the benefits of surgery for treatment of adenomyosis, this
291 systematic review specifically compared the effect of surgery on reproductive outcomes among
292 patients desiring fertility with focal and diffuse AD. Overall, we included a large cohort of studies
293 including 258 women with focal AD and 176 women with diffuse AD. However, over half of the
294 included studies (56.3%) were retrospective and observational case series, each with small

295 sample sizes and lacking matched controls. Significant variations in surgical techniques (Table 2)
296 and surgeon ability to preserve healthy myometrium in cases of conservative fertility-preserving
297 surgery further limited comparability between studies. Unfortunately, no randomized controlled
298 trials exist on the topic of reproductive outcomes after both medical and surgical treatment for
299 patients with focal and diffuse AD.

300 All studies were limited by heterogeneity in patient selection, imaging criteria used to diagnose AD,
301 and lack of reporting of important clinical variables. For instance, the gold standard non-invasive
302 technique for diagnosing adenomyosis and ruling out other pathology is magnetic resonance
303 imaging (MRI) [48,49], yet over 40% of included studies used TVUS alone for diagnosis which may
304 not have the resolution of identifying mild AD or co-occurring factors such as endometriosis,
305 thereby potentially misclassifying many patients as normal. Furthermore, maternal age, ovarian
306 response to medication, and embryo quality were also not adjusted for and may explain
307 discrepancies in the reported results among studies reporting ART outcomes. Finally, significant
308 clinical variables such as average time from surgical intervention to conception and number of ART
309 cycles required for successful pregnancy were rarely reported. Among the 3 studies that evaluated
310 reproductive outcomes after surgery, the average time-to-conception was 44.4 months, with the
311 observation that fertility rates decrease substantially within the first 12 months after surgery.
312 Nevertheless, the follow-up period among most studies was inadequate and the availability of this
313 data would greatly influence whether NC or ART should be recommended following surgery for
314 AD.

315 **CONCLUSION**

316 Based on a review of the currently available evidence, the benefits of conservative surgical
317 management for improving fertility outcomes in patients with focal and diffuse AD appear to vary
318 greatly based on individual patient and provider characteristics. Patients with focal AD may
319 experience improved pregnancy rates and fewer adverse pregnancy outcomes after conservative
320 surgery compared to those with diffuse AD, although further research is required to support this
321 finding and there remains insufficient evidence to support the routine use of conservative surgery

322 in either group to improve reproductive outcomes over expectant or medical management. Our
323 results also demonstrate that there is insufficient evidence to support the use of ART over
324 expectant management after fertility-sparing surgery. Nonetheless, clinicians may benefit from
325 differentiating cases of focal and diffuse adenomyosis to better counsel patients about the risks
326 and benefits of specific treatment strategies.

327 Until well-controlled large-scale studies are available on AD-associated infertility, surgical
328 management should be tailored on a case-by-case basis for each patient's presentation and goals
329 of treatment. In view of the debatable benefits of conservative surgery if fertility is desired and the
330 risk of adverse pregnancy outcomes, medical treatment should remain the first-line option for
331 patients to preserve fertility and relieve symptoms. Conservative surgery may be a reasonable
332 option both for younger patients with concurrent dysmenorrhea or menorrhagia, or in cases of
333 repeated implantation failure, repeated pregnancy loss, and refractory infertility or adenomyosis
334 despite previous treatments; however, further research is required to definitively evaluate the
335 benefits of conservative surgery in each of these populations. Finally, surgeons should be cautious
336 to balance maximum cytoreduction while also conserving adequate tissue to maintain uterine
337 integrity and patients should be appropriately counseled about the potential increased risk of
338 adverse pregnancy events such as uterine rupture, particularly in cases of significant resection for
339 diffuse adenomyosis. Given the complexity of the disease process and the co-occurrence of many
340 confounding conditions such as endometriosis, adenomyosis is a uniquely challenging condition to
341 study and future research should seek to focus on whether specific patient characteristics can be
342 identified to better inform clinical decision making and maximize treatment benefit.

343

344 REFERENCES


- 345 1. Kissler S, Hamscho N, Zangos S, Wiegatz I, Schlichter S, Menzel C, Doeberth N,
346 Gruenwald F, Vogl TJ, Gaetje R, Rody A, Siebzehruebl E, Kunz G, Leyendecker G,
347 Kaufmann M. Uterotubal transport disorder in adenomyosis and endometriosis--a cause for
348 infertility. *BJOG : an international journal of obstetrics and gynaecology*. 2006;113(8):902-
349 908.
- 350 2. Campo S, Campo V, Benagiano G. Infertility and adenomyosis. *Obstetrics and gynecology*
351 *international*. 2012;2012:786132.
- 352 3. Benaglia L, Cardellicchio L, Leonardi M, Faulisi S, Vercellini P, Paffoni A, Somigliana E,
353 Fedele L. Asymptomatic adenomyosis and embryo implantation in IVF cycles.
354 *Reproductive biomedicine online*. 2014;29(5):606-611.
- 355 4. Struble J, Reid S, Bedaiwy MA. Adenomyosis: A Clinical Review of a Challenging
356 Gynecologic Condition. *Journal of minimally invasive gynecology*. 2016;23(2):164-185.
- 357 5. Kunz G, Beil D, Huppert P, Noe M, Kissler S, Leyendecker G. Adenomyosis in
358 endometriosis--prevalence and impact on fertility. Evidence from magnetic resonance
359 imaging. *Hum Reprod*. 2005;20(8):2309-2316.
- 360 6. Pontis A, D'Alterio MN, Pirarba S, de Angelis C, Tinelli R, Angioni S. Adenomyosis: a
361 systematic review of medical treatment. *Gynecological endocrinology : the official journal of*
362 *the International Society of Gynecological Endocrinology*. 2016;32(9):696-700.
- 363 7. Abbott JA. Adenomyosis and Abnormal Uterine Bleeding (AUB-A)-Pathogenesis,
364 diagnosis, and management. *Best practice & research Clinical obstetrics & gynaecology*.
365 2017;40:68-81.
- 366 8. Tsui KH, Lee FK, Seow KM, Chang WC, Wang JW, Chen SU, Chao HT, Yen MS, Wang
367 PH. Conservative surgical treatment of adenomyosis to improve fertility: Controversial
368 values, indications, complications, and pregnancy outcomes. *Taiwanese journal of*
369 *obstetrics & gynecology*. 2015;54(6):635-640.
- 370 9. Al Jama FE. Management of adenomyosis in subfertile women and pregnancy outcome.
371 *Oman medical journal*. 2011;26(3):178-181.
- 372 10. Tremellen K, Russell P. Adenomyosis is a potential cause of recurrent implantation failure
373 during IVF treatment. *The Australian & New Zealand journal of obstetrics & gynaecology*.
374 2011;51(3):280-283.
- 375 11. Kishi Y, Yabuta M, Taniguchi F. Who will benefit from uterus-sparing surgery in
376 adenomyosis-associated subfertility? *Fertility and sterility*. 2014;102(3):802-807 e801.
- 377 12. Osada H, Silber S, Kakinuma T, Nagaishi M, Kato K, Kato O. Surgical procedure to
378 conserve the uterus for future pregnancy in patients suffering from massive adenomyosis.
379 *Reproductive biomedicine online*. 2011;22(1):94-99.
- 380 13. Saremi A, Bahrami H, Salehian P, Hakak N, Pooladi A. Treatment of adenomyomectomy in
381 women with severe uterine adenomyosis using a novel technique. *Reproductive*
382 *biomedicine online*. 2014;28(6):753-760.
- 383 14. Alvi FA, Glaser LM, Chaudhari A, Tsai S, Milad MP. New paradigms in the conservative
384 surgical and interventional management of adenomyosis. *Current opinion in obstetrics &*
385 *gynecology*. 2017;29(4):240-248.
- 386 15. Vercellini P, Consonni D, Drudi D, Bracco B, Frattaruolo MP, Somigliana E. Uterine
387 adenomyosis and in vitro fertilization outcome: a systematic review and meta-analysis.
388 *Human reproduction*. 2014;29(5):964-977.
- 389 16. Younes G, Tulandi T. Conservative Surgery for Adenomyosis and Results: A Systematic
390 Review. *J Minim Invasive Gynecol*. 2017.
- 391 17. Dueholm M. Uterine adenomyosis and infertility, review of reproductive outcome after in
392 vitro fertilization and surgery. *Acta obstetrica et gynecologica Scandinavica*.
393 2017;96(6):715-726.
- 394 18. Younes G, Tulandi T. Effects of adenomyosis on in vitro fertilization treatment outcomes: a
395 meta-analysis. *Fertil Steril*. 2017;108(3):483-490.e483.
- 396 19. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M,
397 Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic

- 398 reviews and meta-analyses of studies that evaluate health care interventions: explanation
399 and elaboration. *PLoS medicine*. 2009;6(7):e1000100.
- 400 20. Wang PH, Liu WM, Fuh JL, Cheng MH, Chao HT. Comparison of surgery alone and
401 combined surgical-medical treatment in the management of symptomatic uterine
402 adenomyoma. *Fertil Steril*. 2009;92(3):876-885.
- 403 21. Nishida M, Takano K, Arai Y, Ozone H, Ichikawa R. Conservative surgical management for
404 diffuse uterine adenomyosis. *Fertility and sterility*. 2010;94(2):715-719.
- 405 22. Dai Z, Feng X, Gao L, Huang M. Local excision of uterine adenomyomas: a report of 86
406 cases with follow-up analyses. *Eur J Obstet Gynecol Reprod Biol*. 2012;161(1):84-87.
- 407 23. Tamura H KH, Kitade M, Asai-Sato M, Tanaka A, Murakami T, et al. . Clinical outcomes of
408 infertility treatment for women with adenomyosis in Japan. . *Reproductive Medicine and
409 Biology*. 2017;16(3):276-282.
- 410 24. Chang WH, Wang KC, Lee NR, Huang N, Su WH, Chao HT, Yen MS, Fuh JL, Wang PH.
411 Reproductive performance of severely symptomatic women with uterine adenomyoma who
412 wanted preservation of the uterus and underwent combined surgical-medical treatment.
413 *Taiwanese journal of obstetrics & gynecology*. 2013;52(1):39-45.
- 414 25. Fujishita A, Masuzaki H, Khan KN, Kitajima M, Ishimaru T. Modified reduction surgery for
415 adenomyosis. A preliminary report of the transverse H incision technique. *Gynecologic and
416 obstetric investigation*. 2004;57(3):132-138.
- 417 26. Huang X, Huang Q, Chen S, Zhang J, Lin K, Zhang X. Efficacy of laparoscopic
418 adenomyomectomy using double-flap method for diffuse uterine adenomyosis. *BMC
419 women's health*. 2015;15:24.
- 420 27. Fedele L, Bianchi S, Zanotti F, Marchini M, Candiani GB. Fertility after conservative surgery
421 for adenomyomas. *Human reproduction (Oxford, England)*. 1993;8(10):1708-1710.
- 422 28. Rajuddin TZJ. Management of adenomyosis in infertile women: comparison between
423 laparotomic resection and administration of aromatase inhibitor (Experience in 55 cases).
424 *Med J Indones*. 2006;15(19-23).
- 425 29. Guy MM YZ, Yan WX, Hui FZ, Hai WX, Ping LY, Chun ZY, Aurelie KK, Tao WZ.
426 Effectiveness of treatment for infertility using clinical investigation of laparoscopy
427 cytoreductive surgery combined with gestrinone in adenomyosis. *Gynecol Surg*.
428 2016;13:451-456.
- 429 30. Takeuchi H, Kitade M, Kikuchi I, Shimanuki H, Kumakiri J, Kitano T, Kinoshita K.
430 Laparoscopic adenomyomectomy and hysteroplasty: a novel method. *Journal of minimally
431 invasive gynecology*. 2006;13(2):150-154.
- 432 31. Takeuchi H, Kitade M, Kikuchi I, Kumakiri J, Kuroda K, Jinushi M. Diagnosis, laparoscopic
433 management, and histopathologic findings of juvenile cystic adenomyoma: a review of nine
434 cases. *Fertility and sterility*. 2010;94(3):862-868.
- 435 32. Wang PH, Fuh JL, Chao HT, Liu WM, Cheng MH, Chao KC. Is the surgical approach
436 beneficial to subfertile women with symptomatic extensive adenomyosis? *The journal of
437 obstetrics and gynaecology research*. 2009;35(3):495-502.
- 438 33. hadisaputra w AT. ILaparoscopic resection versus myolysis in the management of
439 symptomatic uterine adenomyosis: alternatives to conventional treatment. *med J Indones*.
440 2006;15(9-17).
- 441 34. Mehaseb MK, Bell SC, Brown L, Pringle JH, Habiba M. Phenotypic characterisation of the
442 inner and outer myometrium in normal and adenomyotic uteri. *Gynecologic and obstetric
443 investigation*. 2011;71(4):217-224.
- 444 35. Youm HS, Choi YS, Han HD. In vitro fertilization and embryo transfer outcomes in relation
445 to myometrial thickness. *Journal of assisted reproduction and genetics*. 2011;28(11):1135-
446 1140.
- 447 36. Harada T, Khine YM, Kaponis A, Nikellis T, Decavalas G, Taniguchi F. The Impact of
448 Adenomyosis on Women's Fertility. *Obstetrical & gynecological survey*. 2016;71(9):557-
449 568.
- 450 37. Grimbizis GF, Mikos T, Tarlatzis B. Uterus-sparing operative treatment for adenomyosis.
451 *Fertility and sterility*. 2014;101(2):472-487.
- 452 38. Harada T, Khine YM, Kaponis A, Nikellis T, Decavalas G, Taniguchi F. The Impact of
453 Adenomyosis on Women's Fertility. In: *Obstet Gynecol Surv*. Vol 71.2016:557-568.

- 454 39. Park CW, Choi MH, Yang KM, Song IO. Pregnancy rate in women with adenomyosis
455 undergoing fresh or frozen embryo transfer cycles following gonadotropin-releasing
456 hormone agonist treatment. *Clinical and experimental reproductive medicine*.
457 2016;43(3):169-173.
- 458 40. Khan KN KM, Hiraki K, Fujishita A, Sekine I, Ishimaru T, et al. . Changes in tissue in
459 ammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma
460 after GnRH agonist therapy. . *Hum Reprod* 2010. 2010;25:642-653.
- 461 41. Mochimaru A, Aoki S, Oba MS, Kurasawa K, Takahashi T, Hirahara F. Adverse pregnancy
462 outcomes associated with adenomyosis with uterine enlargement. *The journal of obstetrics
463 and gynaecology research*. 2015;41(4):529-533.
- 464 42. Hashimoto A, Iriyama T, Sayama S, Nakayama T, Komatsu A, Miyauchi A, Nishii O,
465 Nagamatsu T, Osuga Y, Fujii T. Adenomyosis and adverse perinatal outcomes: increased
466 risk of second trimester miscarriage, preeclampsia, and placental malposition.
467 <http://dxdoiorg/101080/1476705820171285895>. 2017.
- 468 43. Tamura H, Japan YUGSoMDoOaGU, Kishi H, Japan GUGSoMDoOaGM, Kitade M, Japan
469 JUSoMDoOaGT, Asai- Sato M, Japan YCUHDoOaGY, Tanaka A, Japan IfASMOaGCF,
470 Murakami T, Japan SUoMSDoOaGO, Minegishi T, Japan GUGSoMDoOaGM, Sugino N,
471 Japan YUGSoMDoOaGU. Complications and outcomes of pregnant women with
472 adenomyosis in Japan. *Reproductive Medicine and Biology*. 2017;16(4):330-336.
- 473 44. Hashimoto A, Iriyama T, Sayama S, Nakayama T, Komatsu A, Miyauchi A, Nishii O,
474 Nagamatsu T, Osuga Y, Fujii T. Adenomyosis and adverse perinatal outcomes: increased
475 risk of second trimester miscarriage, preeclampsia, and placental malposition. *The journal
476 of maternal-fetal & neonatal medicine : the official journal of the European Association of
477 Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the
478 International Society of Perinatal Obstet*. 2018;31(3):364-369.
- 479 45. Nikolaou M, Kourea HP, Antonopoulos K, Geronatsiou K, Adonakis G, Decavalas G.
480 Spontaneous uterine rupture in a primigravid woman in the early third trimester attributed to
481 adenomyosis: a case report and review of the literature. *The journal of obstetrics and
482 gynaecology research*. 2013;39(3):727-732.
- 483 46. Thain S, Tan HH. Approaches to adenomyomectomy. *Gynecology and Minimally Invasive
484 Therapy*. 2015;4(3):49-54.
- 485 47. Wang PH, Yang TS, Lee WL, Chao HT, Chang SP, Yuan CC. Treatment of infertile women
486 with adenomyosis with a conservative microsurgical technique and a gonadotropin-
487 releasing hormone agonist. *Fertil Steril*. 2000;73(5):1061-1062.
- 488 48. Dueholm M, Lundorf E. Transvaginal ultrasound or MRI for diagnosis of adenomyosis.
489 *Current opinion in obstetrics & gynecology*. 2007;19(6):505-512.
- 490 49. Andreotti RF, Fleischer AC. The sonographic diagnosis of adenomyosis. *Ultrasound
491 quarterly*. 2005;21(3):167-170.
492

493


494

495 **Figure 1.** PRISMA flow diagram showing the search for studies.

496

497

498 **Figure 2.** Mean fertility outcomes following surgery alone vs combined surgery & medical
499 treatment for women diffuse and focal adenomyosis.



500

501 *Excludes Guy 2016 as that study does not give successful delivery and miscarriage numbers.


502

503

504

505 **Figure 3:** Mean reproductive outcomes for focal vs diffuse adenomyosis. (a) Total (b) Natural
506 conception vs ART.

507
508



509
510 *Excludes Guy 2016 which did not provide successful delivery and miscarriage outcomes.

511

512 **Table 1:** Overview of studies reporting pregnancy outcomes for focal and diffuse adenomyosis after fertility preserving surgery.

Author	Study design	No. of patients (n)	Mean age +- SD (years) (range)	Mean Follow up (months) (range)	Method of diagnosis	Any other pathology
<i>Focal AD</i>						
Fedele et al. 1993	Retrospective	28	35.1	53.2 +- 23.5	N/A	Endometriosis 6 (21.4%) Mullerin anomalies 5 (17.8%) Myomas 7 (25.0%)
Takeuchi et al. 2006	Prospective	14	36 (28-39)	-	TVUS & MRI.	Endometriosis n=9 (64.3%)
Wang et al. 2009 'comparison'	Prospective nonrandomized study.	165	38.3	24	TVUS & AbdUS/AbdUS only	No.
Takeuchi et al. 2010	Prospective long-term follow up	9	25.2 (20-30)	35.9	TVUS & MRI	Endometriosis n=5. Endometrioma n=1.
Al Jama et al. 2011	Non-randomized retrospective	18	38.1 +- 0.9	36	MRI + TVUS	N/A
Dai et al. 2012	Prospective	86	38 (27-48)	24.77 (6-60)	TVUS	N/A
Kishi et al. 2014	Retrospective cohort study	102	37.6	24 (9-60)	MRI	Endometriosis 66 (64.7%)
Guy et al 2016 Surgery + medical Surgery only	Retrospective	27 25	35.9 +-7.4 36.5 +-7.93	24	US not specified	No, those with other diseases excluded.
Chang et al. 2013 *	Prospective	56	38.3 +- 4.6	36	TVUS & AbdUS/AbdUS only	No. Those with other diseases were excluded.
<i>Diffuse AD</i>						
Hadisaputra et al 2006	Prospective	10	37.7 +-7.7 (range 32-48)	N/A	TVUS	N/A
Rajuddin et al 2006 Surgery	Retrospective	32	35.3+-0.7 (28-50)	N/A	TVUS	N/A
Wang et al. 2009 'is the'	Retrospective non-randomized	28	34.3 +- 2.1	36	TVUS	N/A
Nishida et al. 2010	Retrospective clinical study	44	37.1 (range 29-45)	3	MRI	Yes, but unknown what and prevalence.
Osada et al. 2011	Prospective case control	104	37.6	>120	MRI & TVUS	-

Huang et al. 2012	Retrospective	9	34.2 (range 31-37)	62-83	TVUS	-
Saremi et al. 2014	Prospective	103	37.46	24 (20-50)	TVUS & AbdUS & HSP	Leiomyoma n=N/A
<i>Both focal and diffuse AD</i>						
Fujishita et al 2004	Retrospective	11 T	32.3	45.6 (range 23-69)	TVUS and/or MRI	-
	Classic method	5	30.4			
	'H' method	6	33.8			
Total (n) **	Restrospective 9 (56.3%)	815	647.0	571.5	TVUS 7 (43.8%)	
Mean **		n/a	34.1	44.0	MRI 2 (12.5%)	
Range **	Prospective 7 (43.8%)	9-165	20-51	3->120	TVU and/or MRI 1 (12.5%)	
					TVUS & MRI 5 (31.3%)	
					US not specified 1 (12.5%)	
					N/A 1 (12.5%)	
Tamura et al. 2017* Focal and Diffuse AD	Retrospective multicenter study (response rate 16.5%)	84	34.8 +4.2	N/A	TVUS only or TVUS & MRI.	No, other those with endometriosis and leiomyoma were excluded.

513 CS; caesarean section. NVD; normal vaginal delivery. TVUS; transvaginal ultrasound scan. AbdUS; abdominal ultrasound scan. MRI; magnetic resonance imaging.

514 NC; natural conception. ART; assisted reproductive techniques. U; unknown whether ART or natural conception. T; total.

515 *Contains patients from previously published studies.

516 ** Where applicable, only for women undergoing surgery, not medical only.

517

518

519 **Table 2.** Further details of included studies.

Author	Surgical technique used	Pathologic confirmation	Lesion size	Lesion location	Other treatments	Operative complication	Symptoms pre-surgery
<i>Focal AD</i>							
Fedele et al. 1993	Adenomyomectomy according to microsurgical principles. All other coexisting pathologies (eg. endometriosis) were treated at time of surgery.	Yes	Range: 2-15	Subserosal (n=4; 14.3%) Intramural (n=23; 82.1%) Submucous (n=1; 3.6%)	No	-	Recurrent abortion (n=6; 21.4%) Primary infertility (n=7; 25.0%) Secondary infertility (n=4; 14.2%)
Takeuchi et al. 2006	Laparoscopic adenomyomectomy	-	4.7	Ant wall (n=6; 42.9%) Post wall (n=8; 57.1%)	GnRH-a pre-op (n=9; 64.3%) COCP pre-op (n=1; 7.1%)	None	Dysmenorrhea (n=14; 100%) Menorrhagia (n=8; 57.1%) Infertility (n=8; 57.1%) (median period 47 months)
Wang et al. 2009 'comparison'	Adenomyomectomy. Minilaprotomy, ultraminilaprotomy and laproscopic techniques.	Yes	-	Anterior wall (n=25; 15.2%) Posterior wall (n=121; 73.3%) Fundal (n=19; 11.5%)	± GnRH-a 6 months post-op	-	Only included if 20-45 years old. Significantly different age and lesion diameters between groups.
Takeuchi et al. 2010	Laparoscopic enucleation of the cyst (form of adenomyomectomy)	Yes	3.2	' Right side' (n=6) ' left side' (n=3)	GnRH-a (n=3; 33.3%) Oral contraceptive (n=3; 33.3%)	None	Pelvic pain (n=6; 66.7%) Dyspareunia
Al Jama et al. 2011	Adenomyomectomy via microsurgical technique	Yes	Uterus max diameter 10.4 +- 7.3	' Most in anterolateral wall'	GnRH-a 6 months post op.	-	Infertility length 11.4±2.7 years
Dai et al. 2012	Laparotomy adenomyomectomy.	Yes	-	-	No	Endometrial perforation (n=35; 40.7)	Dysmenorrhea. Menorrhagia (n=34; 39.5%)
Kishi et al. 2014	Laparoscopic adenomyomectomy	Yes	-	Anterior wall (n=34; 33.3%) Posterior wall (n=78; 76.5%) Both walls (n=20; 19.6%)	No	Placenta accreta (n=2; 2.0%) Threatened preterm delivery (n=2; 2.0%)	Recurrent miscarriage, infertility.
Guy et al 2016	Laparoscopic Adenomyomectomy.	-	-	-	±Gestrinone 3ms	-	-
Chang et al. 2013 *	Ultramini- or mini-laparotomy adenomyomectomy.	Yes	-	Anterior wall (n=18; 32.1%) Posterior wall (n=30; 53.6%) Fundal (n=8; 14.3%)	6 month course GnRH-a post op.	Uterine perforation (n=17; 30.4%)	Women aged 20-45. Desired fertility and no ART post-op.
<i>Diffuse AD</i>							
Hadisaputra et al 2006	Laparoscopic resection	N/A	153.42g (15-799)	N/A	GnRH-a 3months post op.	-	Dysmenorrhea (n=10; 100%) Menorrhagia (n=6; 60%) Pelvic pain (n=3; 30%)
Rajuddin et al 2006	Cytoreductive.	Yes	Volume 28.9±3.8mm3	-	GnRH-a 4wk pre+post-op Aromatase 3months	-	Length of infertility 86.9±85 months

Wang et al. 2009 'is the'	laparotomy cytoreductive microsurgical technique.	Yes	Uterine size 10.17±0.92	-	GnRH-a 6months post-op (n=15; 53.6%)	Uterine perforation (30%)	' unexplained infertility' severe dysmenorrhea
Nishida et al. 2010	Laparotomy. Asymmetric dissection of uterus sacrificing a fallopian tube. No tourniquets. Concurrent peri-uterine adhesiolysis (n=13), myomectomy (n=8), chocolate cystectomy (n=8).	Yes	-	-	N/A	Transfusion 7 (15.9%)	Dysmenorrhea (100%)
Osada et al. 2011	Mini-laparotomy cytoreductive technique via ' triple-flap' method. Tourniquet applied to uterine vessels.	Yes	-	Ant wall (n=38; 36.5%) Post wall (n=44; 42.3%) Both (n=22; 21.2%)	N/A	Haematoma <1cm diameter 6 (5.8)	Prev IVF (n=57), embryo transfer (n=45), miscarried (n=17). Other ART (n=11), miscarried (n=3) Anemia (n=94; 90.4%) Dysmenorrhea (n=104; 100%) Menorrhagia (n=104; 100%)
Huang et al. 2012	Microscopic cytoreductive + GnRH-a postoperatively	-	-	-	GnRH-a for 6 months post-operatively in all.	None	>3 year history of infertility (n=9; 100%). Dysmenhorea (n=9; 100%) Menorrhagia (n=8; 88.9%)
Saremi et al. 2014	Uterine artery tourniquet used. Cytoreductive via Laparotomy.	-	-	Ant and post wall (n=3; 2.9%)	No	Asherman's (n=4; 3.8%) Uterine rupture (n=2; 1.9%)	Infertility (n=57; 55.3%) Recurrent miscarriage (n=9; 8.7%) IVF failure (n=17; 16.5%) Menorrhagia (n=20; 19.4%)
<i>Focal & Diffuse AD</i>							
Fujishita et al 2004	Laparotomy. Cytoreductive ' H' technique and indigo-carmin catheter to assess endometrial perforation or classic cytoreductive.	-	-	-	No	Uterine perforation (n= 3; 27.3%)	' most' had dysmenorrhea menorrhagia and infertility
Tamura et al. 2017 * Both AD	Doesn't describe techniques used.	-	-	-	N/A	-	All women were to have ' infertility treatment' .

520 CS; caesarean section. NVD; normal vaginal delivery. TVUS; transvaginal ultrasound scan. AbdUS; abdominal ultrasound scan. MRI; magnetic resonance imaging.
521 NC; natural conception. ART; assisted reproductive techniques. U; unknown whether ART or natural conception. T; total.
522 *Contains patients from previously published studies.
523

524 **Table 3.** Pregnancy outcomes following surgery for focal and diffuse adenomyosis.

Author	Patients desiring fertility (n)	Women becoming pregnant (n) (% as proportion of women desiring fertility)	Successful deliveries (n) (% as proportion of women desiring fertility)	Term deliveries (n) (% as proportion of women desiring fertility)	Miscarriages/abortions (n) (% as proportion of total pregnancies)	Preterm deliveries (n) (% as proportion of women desiring fertility)	Obstetric outcomes	Delivery method	Birth weight (g)
<i>Focal AD</i>									
Fedele et al. 1993 Total	18	13 (72.2%) women (18 pregnancies)	9 (50%)	9 (50%)	8 (44.4%)	1 (5.6%)	1 preterm = neonatal death. 1 ectopic.	CS 3 (33.3%) NVD 6 (66.7%)	-
Natural conception	17	12 (70.6%)	9 (52.9%)	9 (52.9%)	7 (1 an ectopic) (41.4%)	1 (5.9%)	-	-	-
ART	1	1 (100.0%)	0 (0.0%)	0 (0.0%)	1 (100%)	0	-	-	-
Fujishita et al 2004 total	6	1 (16.7%)	1 (16.7%)	1 (16.7%)	0	0	-	CS 1	-
Natural conception									
Takeuchi et al. 2006 Natural conception	14	2 (14.3%)	1 (50.0%)	1 (50.0%)	0	0	Live female; 1 (50.0%) Ongoing pregnancy at follow up; 1 (50.0%)	NVD 1	2856
Wang et al. 2009 'conservative' Natural conception	71	55 (77.5%)	49 (69.0%)	42 (59.2%)	6 (10.9%)	7 (9.9%)	-	-	-
Surgery alone	27	20 (74.1%)	17 (63.0%)	15 (55.6%)	3 (15.0%)	2 (7.4%)	-	-	-
Surgical-medical	44	35 (79.5%)	32 (72.7%)	27 (61.4%)	3 (8.6%)	5 (11.4%)	-	-	-
Takeuchi et al. 2010 Natural conception	3	2 (66.7%) (3 preg but 2 to 1 woman)	3 (100.0%) (3 preg in total)	3 (100.0%)	0	0	-	NVD 2 CS 37wks 1	-
Al Jama et al. 2011 Natural conception Surgical medical	18	8 (44.4%)	6 (33.3%)	6 (33.3%)	2 (25.0%)	0	Ectopic; 1 (9.1%) Retained placenta following NVD; 1 (9.1%)	CS 6 NVD 1 w/ retained placenta	-
Kishi et al. 2014 Total Unknown NC/ART	*** 102	*** 42 (41.2%)	*** 32 (31.4%)	-	*** 10 (23.8%)	*** 4 (3.9%)	Preterms; Placenta accreta 2 (2.0%) 2 (2.0%) threatened preterm labours delivered wks 35 & 36.	CS all.	-
Guy et al 2016 Natural conception							-	-	-
Surgery + medical	14	8 (57.1%)	N/A	N/A	N/A	N/A			
Surgery	12	5 (41.7%)	N/A	N/A	N/A	N/A			

Totals surgery**				**	**	**	-	-	
All	258	136 (52.7%)			26 (19.1%)				
Natural	155	93			15				
ART	1	1			1				
Unknown	102	42			10				
Chang et al. 2013 *	56	23 (41.1%) (27 pregnancies).	15 (26.8%)	13 (23.2%)	12 (44.4%); 7 elective (25.9%) 4 spont (14.8%) 1 ectopic (3.7%)	2 (3.6%)	1 ectopic pregnancy 2 preterm	-	-
Natural conception									
Tamura et al.2017*	***	***	-	-	***	-	-	-	-
Unknown ART/NC	23	9 (39.1%)			0 (0.0%)				
<u>Diffuse AD</u>									
Fujishita et al 2004									
Natural conception	1	1 (100%)	-	-	-	-	Pregnancy ongoing at follow up	-	-
Hadisaputra et al 2006	10	3 (30.0%)	1 (10.0%)	1 (10.0%)	1 (33.3%) (5 wks)	1 (10.0%) 30 wks neonatal death	PROM 1 (10.0%)	CS 1	3500
Natural conception									
Rajuddin et al 2006	32	3 (9.4%)	2 (6.3%)	N/A	1 (33.3%)	N/A	-	N/A	-
Natural conception									
Wang et al. 2009 'is the'	28	13 (46.4%)	9 (32.1%)	-	4 (30.8%)	-	-	-	-
Natural conception									
Surgery +/- medical									
Osada et al. 2011 total	26	16 (61.5%)	14 (53.8%)	-	2 (12.5%)	0	0	CS 14	-
Natural conception	-	4	4	-	0	0	0	-	-
ART	-	12	10	-	2 (16.7%)	0	0	-	-
Huang et al. 2012 total	9	3 (33.3%)	2 U (22.2%) ***	-	1 U (33.3%) ***	-	-	CS 2	-
Natural conception	3	1 (33.3%)	N/A	-	N/A	-	-	-	-
ART	6	2 (33.3%)	N/A	-	N/A	-	-	-	-
Saremi et al. 2014	70	21 (30.0%)	16 U (22.9%) ***	17 U (24.3%) ***	4 U (19.0%) ***	1 U (1.4%) ***	Uterine rupture 2 (9.5%); 37 wks (still birth) & 32 wks (baby survived)	CS 17.	-
Natural conception	21	7 (33.3%)	N/A	N/A	N/A	N/A	-	-	-
ART	49	14 (28.6%)	N/A	N/A	N/A	N/A	-	-	-
Totals following surgery				-					
All	176	60 (34.1%)	44 (25.0%)	**	13 (21.7%)	**	Uterine rupture 2 PROM 2	CS in all studies that specify	-
Natural	95	32	16		6				
	55	28	10		2				

ART Unknown	26	-	18 ***		5 ***				
Tamura et al. 2017* unknown ART/NC	61	*** 24 (39.3%)	-	-	*** 10/31 (32.3%)	-	-	-	-

525 CS; caesarean section. NVD; normal vaginal delivery. TVUS; transvaginal ultrasound scan. AbdUS; abdominal ultrasound scan. MRI; magnetic resonance imaging. NC; natural
526 conception. ART; assisted reproductive techniques. U; unknown whether ART or natural conception. T; total.

527 *Contains patients from previously published studies.

528 ** poorly reported so cannot be accurately calculated.

529 *** unknown if ART/NC; where the study reported pregnancy/delivery/miscarriage rates but did not specify whether in women with ART or with natural conception (NC).

530

531

532

533 **Table 4. Summary conclusions & topics for future research.**

1. Management of women with adenomyosis-associated subfertility is highly controversial and there remains an overall lack of consensus regarding the value of conservative surgery and/or medical management to improve reproductive outcomes.
2. Based on currently available evidence, conservative surgery should not be routinely recommended if fertility is desired. It may be considered on a case-by-case basis for patients with concurrent AD-associated pelvic pain or menorrhagia, younger infertile women who have failed medical management or older women with infertility despite ART, and those with a history of recurrent pregnancy loss (RPL) or recurrent implantation failure (RIF).
3. There is insufficient evidence to recommend ART over expectant management after conservative surgery for both focal and diffuse adenomyosis given similar pregnancy rates observed.
4. Patients with adenomyosis are at increased risk of adverse perinatal outcomes including preterm birth, PPRM, pre-eclampsia, and spontaneous miscarriage.
5. Patients with diffuse adenomyosis may be at an increased risk of antepartum or intrapartum uterine rupture after cytreductive surgery compared to patients with focal adenomyosis after adenomyomectomy. This is likely related to the volume of tissue resected. However, the overall risk of uterine rupture is unknown and requires further study.
6. Reproductive surgeons should be cognizant to balance maximal cytreduction while also conserving adequate uterine tissue to minimize the risk of adverse pregnancy outcomes.

534

535 **Supplemental Figures and Tables**536 **Supplemental Figure 1:** Reproductive outcomes following surgery for diffuse and focal AD.

537 *Denotes missing data for successful delivery and/or miscarriage rate.

538 **Supplemental Figure 2:** Pregnancy rate for focal vs. diffuse AD after natural conception and ART.539 **Supplemental Table 1:** Methodologic quality assessment of nonrandomized studies for potential
540 risk of bias using the Cochrane Collaboration's Risk of Bias Tools for Non-Randomized Studies.

541

542

Accepted Manuscript